載入...
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Advances in the understanding of the molecular basis for acute myeloid leukemia (AML) have generated new potential targets for treatment. Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are associated with poor overall survival. AXL pla...
Na minha lista:
| 發表在: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer US
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5613053/ https://ncbi.nlm.nih.gov/pubmed/28516360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0470-z |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|